Yesterday, Aclaris Therapeutics provided an update regarding its ATI-502 JAK inhibitor product for the topical treatment of androgenetic alopecia (AGA). It seems like this product was called ATI-50002 in the past? In any event, the main quote:
“AGA-201 Topical – Completed enrollment of this ongoing Phase 2 open-label clinical trial of ATI-502 for the topical treatment of androgenetic alopecia (AGA), also known as male/female pattern hair loss. This trial will evaluate the safety and efficacy of ATI-502 on the regrowth of hair in 31 patients with AGA, and data are expected in the first half of 2019”.
Yesterday, we presented on our financial results for the third quarter of 2018 and provided an update on our clinical development and commercial programs. Read more: https://t.co/MYDDvvUOj2 pic.twitter.com/hJ52HZSKxI
— Aclaris Therapeutics (@aclaristx) November 7, 2018
Based on the hype several years ago, I would have thought that Aclaris would be finishing Phase 2 trials by year-end 2018. Will nevertheless take this news in stride.
Big year in 2019 to weed out the players from the fakers.